Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Philipp D. le Coutre"'
Autor:
Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis Giles, the Study 1053 investigators
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
Abstract Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/re
Externí odkaz:
https://doaj.org/article/036b0eca00dd402a9a89af31dbc023b1
Autor:
Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Francisco Cervantes, François Guilhot, Dietger Niederwieser, Philipp D. le Coutre, Gianantonio Rosti, Gert Ossenkoppele, Clarisse Lobo, Hirohiko Shibayama, Xiaolin Fan, Hans D. Menssen, Charisse Kemp, Richard A. Larson, Giuseppe Saglio
Publikováno v:
Haematologica, Vol 99, Iss 7 (2014)
In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatin
Externí odkaz:
https://doaj.org/article/f9247c6bc3ef4a3180276027f92a7050
Autor:
Andreas Hochhaus, Maria Teresa Gómez Casares, Jesper Stentoft, Eibhlin Conneally, Valentin García-Gutiérrez, Norbert Gattermann, Wieslaw Wiktor-Jedrzejczak, Philipp D. Le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Jerald P. Radich, David M. Ross, Hans D. Menssen, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, Veronique Bedoucha, Giuseppe Saglio
Publikováno v:
Blood. 128:3066-3066
Background: Many patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) achieve a sustained deep molecular response (DMR) with frontline nilotinib (NIL) therapy. ENESTfreedom (NCT01784068) is an ongoing phase 2 study evaluating the po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f6ce0f9205ee2bfcc4ee886a29e3619
https://doi.org/10.1182/blood.v128.22.3066.3066
https://doi.org/10.1182/blood.v128.22.3066.3066
Autor:
Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah
Publikováno v:
Blood. 122:2738-2738
Background Information is generally lacking regarding the efficacy and safety of subsequent TKIs after failure of nilotinib. This post-hoc analysis explored the efficacy and safety of ponatinib, a potent oral pan-BCR-ABL inhibitor, following failure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a73e17282cada1b283afd9fdc30de26
https://doi.org/10.1182/blood.v122.21.2738.2738
https://doi.org/10.1182/blood.v122.21.2738.2738
Autor:
Philipp D. le Coutre, Timothy P. Hughes, Francois-Xavier Mahon, Dong-Wook Kim, Juan Luis Steegmann, Neil P. Shah, Nicola Wallis, Jorge E. Cortes
Publikováno v:
Blood. 122:1489-1489
Background The introduction of BCR-ABL inhibitors revolutionized the treatment of chronic myeloid leukemia (CML) which is now a manageable, chronic disease. As BCR-ABL inhibitors are used more widely and for longer, some distinctly different or late
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ba5c0e18dec65d9462e263b879d13d3
https://doi.org/10.1182/blood.v122.21.1489.1489
https://doi.org/10.1182/blood.v122.21.1489.1489
Autor:
Javier Pinilla-Ibarz, Jorge E. Cortes, Dong-Wook Kim, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, John F. Dipersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian, Moshe Talpaz
Publikováno v:
Blood. 122:4007-4007
Background Ponatinib is a potent oral pan–BCR-ABL tyrosine kinase inhibitor (TKI) that has demonstrated significant clinical activity in heavily pretreated CP-CML pts. A multivariate analysis of CP-CML pts in the PACE trial found significant associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::195f398f467382f45ec674e885119189
https://doi.org/10.1182/blood.v122.21.4007.4007
https://doi.org/10.1182/blood.v122.21.4007.4007
Autor:
Richard A. Larson, Andreas Hochhaus, Giuseppe Saglio, Dong-Wook Kim, Saengsuree Jootar, Philipp D. Le Coutre, Josy Reiffers, Ricardo Pasquini, Stuart L. Goldberg, Richard E. Clark, Charisse N. Kemp, Xiaolin Fan, Hans D. Menssen, Timothy P. Hughes, Hagop M. Kantarjian
Publikováno v:
Journal of Clinical Oncology. 31:7052-7052
7052^ Background: In the 3-y follow-up (f/u) of ENESTnd, NIL demonstrated superior rates of molecular response and reduced progression to accelerated phase/blast crisis (AP/BC) vs IM. Here, we report results with a minimum f/u of 4 y. Methods: 846 ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19306afc5b9425c1dd29a05c61827f6b
https://doi.org/10.1200/jco.2013.31.15_suppl.7052
https://doi.org/10.1200/jco.2013.31.15_suppl.7052